RT Journal Article
SR Electronic
T1 COVID-19 vaccine hesitancy among persons living in homeless shelters in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.29.21256256
DO 10.1101/2021.04.29.21256256
A1 Longchamps, C
A1 Ducarroz, S
A1 Crouzet, L
A1 Vignier, N.
A1 Pourtau, L.
A1 Allaire, C
A1 Colleville, AC
A1 Aarbaoui, T El
A1 Melchior, M
A1 the ECHO study group
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2021.04.29.21256256.abstract
AB COVID-19 vaccine hesitancy is frequent and can constitute a barrier to the dissemination of vaccines once they are available. Unequal access to vaccines may also contribute to socioeconomic inequalities with regard to COVID-19. We studied vaccine hesitancy among persons living in homeless shelters in France between May and June 2020 (n=235). Overall, 40.9% of study participants reported vaccine hesitancy, which is comparable to general population trends in France. In multivariate regression models, factors associated with vaccine hesitancy are: being a woman (OR=2.55; 95% CI 1.40-4.74), living with a partner (OR=2.48, 95% CI 1.17-5.41), no legal residence in France (OR=0.51, 95% CI 0.27-0.92), and health literacy (OR=0.38, 95% CI 0.21, 0.68). Our results suggest that trends in vaccine hesitancy and associated factors are similar among homeless persons as in the general population. Dissemination of information on vaccine risks and benefits needs to be adapted to persons who experience severe disadvantage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe ECHO study received support from the French collaborative Institute on Migration, the French Public Health Agency, and the French National Research Agency (Flash COVID-19).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ECHO study received approval of the Ethical Research Committee of the University of Paris (CER-2020-41).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available from the Principal Investigators upon request.